Edwards Lifesciences (NYSE:EW) Reaches New 52-Week High – Should You Buy?

Edwards Lifesciences Corporation (NYSE:EW)’s share price reached a new 52-week high during trading on Wednesday . The stock traded as high as $90.21 and last traded at $90.44, with a volume of 419047 shares changing hands. The stock had previously closed at $86.95.

Analyst Upgrades and Downgrades

Several research firms recently commented on EW. Canaccord Genuity Group set a $85.00 price objective on Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Barclays reaffirmed an “overweight” rating and set a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. TD Cowen reiterated a “buy” rating and issued a $104.00 price target (up from $97.00) on shares of Edwards Lifesciences in a research note on Tuesday, June 2nd. Robert W. Baird boosted their price objective on shares of Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a report on Friday, April 24th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $95.96.

Edwards Lifesciences Price Performance

The firm has a 50-day simple moving average of $84.16 and a 200-day simple moving average of $83.21. The firm has a market capitalization of $51.68 billion, a PE ratio of 47.74, a PEG ratio of 2.25 and a beta of 0.87. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. During the same quarter in the prior year, the firm earned $0.64 EPS. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president directly owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Andrew M. Dahl sold 568 shares of the business’s stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This represents a 3.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 81,038 shares of company stock valued at $6,683,255. Company insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Elo Mutual Pension Insurance Co lifted its position in Edwards Lifesciences by 39.9% in the third quarter. Elo Mutual Pension Insurance Co now owns 89,674 shares of the medical research company’s stock worth $6,974,000 after buying an additional 25,562 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Edwards Lifesciences by 27.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock worth $9,356,000 after acquiring an additional 23,514 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Edwards Lifesciences by 39.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 2,286,298 shares of the medical research company’s stock worth $194,907,000 after purchasing an additional 648,870 shares during the period. Central Pacific Bank Trust Division bought a new position in Edwards Lifesciences during the 4th quarter valued at about $775,000. Finally, Stance Capital LLC raised its position in Edwards Lifesciences by 373.1% in the 3rd quarter. Stance Capital LLC now owns 45,994 shares of the medical research company’s stock worth $3,577,000 after purchasing an additional 36,272 shares during the period. Institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.